Supriya Life science Ltd.:
Supriya
Lifescience serves the manufacturing of active pharmaceutical ingredients(APIs). the company is the largest exporter of chlorpheniramine maleate and
ketamine hydrochloride from India between the years 2017 to 2021. The company
produces 38 APIs focused on therapeutic segments such as antihistamine,
analgesic, anesthetic, vitamin, anti-asthmatic and anti-allergic.
The company exports its products to 86 countries for 1296 customers with 346 distributors. The main business of API is in Europe, Latin America, Asia, and North America. The company has a manufacturing facility in Maharashtra across 23,806 SQ meters. The manufacturing facility has received approvals from USFDA, EDQM TGA-Australia, KFDA-Korea, PMDA Japan, NMPA-China, and Health Canada.
Financials:
Supriya Lifescience
was the largest exporter of salbutamol sulfate in India, contributing 31% of
the API exports in FY 21. Europe business contributed 17.40%, Latin America 19.15%, Asia 29.27%
(exclude India), North America 4.76%, and India is 22.53% of total revenue in
the year 2021. The company recorded healthy growth in profits
at ₹123.83 crores in FY21, Revenue of the year FY 21 is ₹385.36
crores jumping from ₹311.64 crores in FY20.
Strength:
Valued scale with a leadership
position across key and niche products.
Diversified revenue with a global
presence across 86 countries.
The company has advanced research and
development with manufacturing capabilities.
Consistent strong
financial growth because of de-risk business model.
Key Risk:
The dependency of the company is few customers for a valuable part of revenue.
Inability to accurately forecast demands for its products and manage the inventory.
Failure to successfully develop the product and commercialize also promptly.
Any failure to comply with regulations and regulatory agencies or obtain, maintain or renew its regulatory licenses, permits, approvals required for operating its business.
Supriya Lifescience IPO Details:
The
company will plan to raise the funds aggregating up to ₹700 crores from the
fresh issue. The Supriya Lifescience will be used the net brings in of fresh
issues for capital expenditure and repaying the debts, and general corporate
purpose and offer for sale money will go to the promoter Mr. Satish Waman Wagh.
Currently,
Mr. Satish Waman Wagh holds a 99.26% stake in the company, and promoter groups
hold 0.72% in the firm. The issue has been reserved 75% for qualified
institutional investors, 15% reserved for non-institutional investors, and the
remaining 10% for retail investors.
IPO Opening & Closing Date:
Supriya Lifescience IPO will be open on the 16th
of December 2021 and the investors can be bidding on this IPO till the 20th of
December 2021.
Face Value of the IPO:
The
issue is the book-built type and the face value is ₹2 per equity share.
Price Band of the IPO:
The
Company has been fixed the price of ₹265 to ₹274 per equity share.
IPO Lot Size:
The
market lot size of the IPO is 54 shares and the minimum order quantity is one lot (54 shares).
Investment Limit:
The
investors can bid a minimum of one lot and a maximum of 13 lots in this IPO.
You can invest a minimum of ₹14,796 (₹274x₹54) whereas the maximum investment
allowed in this IPO is ₹1, 92,348 [(₹274x₹54) x13].
IPO Allotment Date:
The
allotment of shares may be expected by 23rd December, unsuccessful investors
will get the refund by 24rd of December 2021. And the lucky investors will
credit the shares in their Demat account on the 27th of December 2021.
IPO Listing Date:
The IPO will be listed in both NSE & BSE on the 28th of December 2021.
How to check the Allotment status?
The company will finalize the allotment of the shares by the 22nd of
December 2021. The investors can check their allotment status on the BSE website or the website of the IPO
registrar.
Select equity share and issue name.
Enter the application number and PAN number.
Finally, check the box (I’m not a robot) and click on the search.
Supriya Lifescience IPO Subscribe or Not?
Supriya
Lifescience is one of the leading manufacturers and suppliers of active
pharmaceutical ingredients (APIs) in India with a focus on research and
development. According
to market experts, it’s a very good company with experienced management and
promoters. Many brokerages are bullish on this IPO because of its good
valuation. The experts suggested that the investors can bid the IPO for
short-term listing gain, big listing gain, and long-term gain also.
MedPlus Health Services Limited :
MedPlus Health Services is the second-largest pharmacy company in India, which is incorporated in 2006.The company. MedPlus offers Pharmaceutical & wellness products like medicine, vitamins, medical devices, test kits, baby care products, and home & personal care products such as sanitizers, soaps, detergents, etc.
And the company is also the first pharmacy retailer in India which offers an omnichannel platform where customers can purchase products through stores, place orders over the phone and online orders. The company has a good pharmacy retail network of 2,165 stores in Tamil Nadu, Andhra Pradesh, Telangana, Karnataka, Odisha, West Bengal, and Maharashtra as of 31st June 2021.
The company reported 30%,29%,30%, and 22% revenue from operations in Chennai, Bangalore, Hyderabad, and Kolkata. The warehouses of the company are in Bengaluru, Chennai, Hyderabad, Vijayawada, Kolkata, Pune, Bhubaneshwar, Mumbai, and Nagpur.
Financial:
The
company has reported a profit of 63.11 crores in FY2021 and a 1.79 crore profit
in FY 2020. The revenue of the company is increased from FY 20 to FY 21 is
3,069.26 crore from 2,870.6 crores. As of 30th September 2021, the company
reported a revenue of 1,890.9 crores and a net profit of 66.36 crores.
Strength:
MedPlus is the second-largest pharmacy retailer company with 2000+ stores.
The company has been positioned to stand for good quality pharmaceutical products with affordable prices for 15+ years.
Successful track record with experienced promoters.
High-density network enhancing omnichannel proposition.
Key Risk:
There have been instances of negative cash flow in the last three financial years.
Failure to manage properly for inventories and anticipate demand.
The risk associated with expansion to the new market.
Dependency on third-party manufacturers for the supply of the products.
IPO Details of MedPlus:
The IPO of MedPlus by the volume and reach, consisting of fresh issue of shares ₹600 Crore and offer for sale of shares ₹798.29 crores. The IPO is open for subscription on 13th December 2021 and it will open for bidding till 15th December 2021.
MedPlus Price Band:
The company management fixed the price band of the IPO at ₹780 to ₹796 per equity share.
MedPlus IPO Size:
The company aims will raise ₹1398.3 crores from the public issue.
Lot Size and Limit:
The investors will be able to apply for a minimum of one lot whereas 18 shares and the minimum investment allowed in this issue is ₹14,328 (₹796x18) and maximum of 13 lots whereas the maximum investment allowed to bidders is ₹1,86264[(₹796x18) x13] of the company.
MedPlus Employee Discount:
The company declares the reservation of shares worth 5 crores for MedPlus employees. The eligible employees will get a discount of the share of 78 per equity share to the final price.
IPO Face Value:
The IPO is a book-built issue type. And the face value of the MedPlus IPO is ₹2 per equity share.
MedPlus IPO Allotment Date:
The expected date of the allotment of the IPO is 20th December 2021. And the initiation of the refund is 21st December for the unsuccessful investors. The credit of shares in Demat account on 22nd December 2021 for the lucky investors
IPO Listing of MedPlus:
The company will be listed on both NSE and BSE, and the expected date of MedPlus Health IPO listing is the 23rd of December 2021.How to check the IPO Allotment Status:
Med-Plus Health will finalize the basis of allotment by the 21st of December 2021. The bidders can check their allotment status either on the BSE website or the website of the IPO registrar.
Select equity share and the Issue name.
Enter the application number and PAN number.
Finally, check the box (I’m not a robot) and click on search.
MedPlus IPO Subscribe or Not:
According to the market‘s observer, MedPlus Health services is the second-largest pharmacy retailer in India in terms of the number of stores and revenue, the company offers a good value proposition to its customers in terms of discounts, a wide range of products & fast delivery. Strong brand reputation, omnichannel platform, and strong financial metrics are some of the strong fundamentals that may favor the IPO and due to positive sentiments, the IPO list with good price.
Many brokerages have positive on MedPlus IPO. They assume that the company’s play pure omnichannel will help to deliver high growth in the future. The company has experienced promoters with good valuations. So, if you think of bidding on the MedPlus Health IPO, then apply this IPO for big listing gain and for long-term gains also.
We hope you like this blog "Things to know before Investing in Supriya Lifescience Ltd. | Med Plus Health IPO". If you have any question or updates, please reach out our site www.tradeipohub.co.in.Thanks for reading.